本帖最后由 老马 于 2013-3-13 13:43 编辑
7 e' G5 L% W: ^% g0 }2 G1 c- K2 `& s: ^5 E- P! F
健择(吉西他滨)+顺铂+阿瓦斯汀6 a/ x4 ~4 c! a/ M* h3 e( Z
Gemzar +Cisplatin + Avastin
$ P- B' X+ u, _, c( S/ |http://annonc.oxfordjournals.org/content/21/9/1804.full
3 K I6 e& m! jOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) ( D: w0 g2 V3 _1 G/ l" w
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. 6 m( E3 g: A5 L; H6 [/ {
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. % V4 V8 @' q, b4 R Q9 E
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 836)
X4 a* B. G; l; o& C7 ^华为网盘附件:" _# A. H$ l1 F7 R
【华为网盘】ava.JPG
7 J1 P: s2 x0 @$ `" Z2 @ |